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Abstract
Background: Amikacin and kanamycin are mainly used for treating multidrug-resistant tuberculosis (MDR-TB),
especially in developing countries where the burden of MDR-TB is highest. Their protracted use in MDR-TB
treatment is known to cause dose-dependent irreversible hearing loss, requiring hearing aids, cochlear implants or
rehabilitation. Therapeutic drug monitoring and regular audiological assessments may help to prevent or detect the
onset of hearing loss, but these services are not always available or affordable in many developing countries. We
aimed to compare the cumulative incidence of hearing loss among patients treated for MDR-TB with amikacin or
kanamycin-based regimens, and to identify the most-at-risk patients, based on the real-life clinical practice
experiences in Namibia.
Methods: We conducted a retrospective cohort study of patients treated with amikacin or kanamycin-based
regimens in four public sector MDR-TB treatment sites in Namibia between June 2004 and March 2014. Patients
were audiologically assessed as part of clinical care. The study outcome was the occurrence of any hearing loss.
Data were manually extracted from patients’ treatment records. We compared proportions using the Chi-square
test; applied stratified analysis and logistic regression to study the risk of hearing loss and to identify the
most-at-risk patients through effect-modification analysis. A P-value < 0.05 was statistically significant.
Results: All 353 patients had normal baseline hearing, 46 % were HIV co-infected. Cumulative incidence of any
hearing loss was 58 %, which was mostly bilateral (83 %), and mild (32 %), moderate (23 %), moderate-severe (16 %),
severe (10 %), or profound (15 %). Patients using amikacin had a greater risk of developing the more severe forms of
hearing loss than those using kanamycin (adjusted odds ratio (OR) = 4.0, 95 % CI: 1.5–10.8). Patients co-infected with
HIV (OR = 3.4, 95 % CI: 1.1–10.6), males (OR = 4.5, 95 %1.5–13.4) and those with lower baseline body weight (40–59 kg,
OR = 2.8, 95 % CI: 1.1–6.8), were most-at-risk of developing hearing loss.
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Conclusion: Amikacin use in the long-term MDR-TB treatment led to a higher risk of occurrence of the more severe
forms of hearing loss compared to kanamycin use. Males, patients with low baseline body weight and those co-
infected with HIV were most-at-risk. MDR-TB treatment programmes should consider replacing amikacin with
kanamycin and strengthen the routine renal, serum therapeutic drug levels and audiometric monitoring in the most-
at-risk patients treated with aminoglycosides.
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Background
Amikacin and kanamycin belong to a group of antibi-
otics called aminoglycosides, which are used in the treat-
ment of Gram-negative bacterial and mycobacterial
infections. These aminoglycosides, in combination with
fluoroquinolones, form the backbone for the treatment
of multidrug-resistant tuberculosis (MDR-TB), as rec-
ommended by the World Health Organization (WHO)
[1–3]. A major safety concern of the aminoglycosides is
their ability to induce ototoxicity, especially during their
long-term use in MDR-TB treatment [4–6]. Depending
on the part of the inner ear that is affected as well as the
selectivity of the aminoglycoside, the ototoxicity could
be auditory or vestibular [7]. The current study focusses
on the auditory toxicity (hearing loss or deafness) caused
by amikacin and kanamycin. Aminoglycoside-induced
hearing loss is permanent, although in some cases; it
may be alleviated by the use of hearing aids, cochlear
implants or speech rehabilitation, which unfortunately,
are costly interventions. By experiencing hearing loss,
patients end-up suffering from a distressful yet prevent-
able drug-related disability that may negatively impact
on their quality of life and limit their capability to work,
for example, in occupations where good hearing ability
is a requirement. In children, speech development may
be severely compromised [8].
Aminoglycosides have a narrow therapeutic index;
hence require careful monitoring of serum levels, par-
ticularly during their prolonged use in MDR-TB treat-
ment, to prevent the occurrence of dose-dependent
ototoxicity [9, 10]. In addition, regular audiologic assess-
ments may help in the early detection of hearing impair-
ment, before the damage becomes extensive and
irreversible [11–13]. Some patients are genetically predis-
posed to suffering from aminoglycoside-induced hearing
loss and genetic typing may be useful in identifying such
patients [14–17]. Yet many patients in developing coun-
tries do not have access to such interventions or cannot
afford them, due to weak public sector health systems and
high levels of poverty [18].
Namibia is a developing country situated in the
south-western part of Africa. It is classified by the
World Bank as an upper middle income country [19].
At the time of this study, there were 13 regional
centers for treating patients diagnosed with MDR-TB.
One of the centers - the Walvis Bay MDR-TB treatment
site - began assessing patients for aminoglycoside-induced
hearing loss in 2004. In 2008, Namibia changed the pre-
ferred aminoglycoside for MDR-TB treatment from ami-
kacin to kanamycin - which was cheaper and more readily
available—and introduced capreomycin as an option for
patients prone to hearing loss. Later in the same year,
other MDR-treatment sites commenced the systematic
audiometric monitoring of patients on MDR-TB treat-
ment for the early detection and management of
aminoglycoside-induced hearing loss. The change from
amikacin to kanamycin; and the introduction of system-
atic audiometry provided us with the opportunity of com-
paring the incidence of hearing loss in patients treated
with amikacin and kanamycin-based MDR-TB regimens
respectively, in real-life programmatic conditions.
Even though amikacin and kanamycin have been in clin-
ical use for over 50 years, surprisingly to-date, the evidence
on their comparative risk of inducing hearing loss is scarce.
Moreover, studies often have not been well done, especially
in terms of measuring the hearing loss and patients with
human immunodeficiency virus (HIV) co-infection have
been underrepresented [6]. In sub-Sahara Africa, where the
HIV and TB burden are still high [20, 21], HIV co-infection
becomes a key consideration in the successful treatment of
MDR-TB [22]. Tuberculosis patients co-infected with
HIV are an important subgroup because of the poten-
tial effect of HIV and antiretroviral treatment on
hearing function [23–27].
The aim of this study was to compare the cumulative
incidence of hearing loss among patients treated for
MDR-TB using amikacin or kanamycin-based regimens,
and to identify those that were most-at-risk. The high
prevalence of HIV co-infection among patients diag-
nosed with MDR-TB in Namibia during the period of
the study also enabled us to examine the influence of
HIV infection on the risk of aminoglycoside-induced
hearing loss.
Methods
Study design and setting
We conducted a retrospective cohort study of MDR-TB
patients treated with amikacin or kanamycin-based
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regimens between June 2004 and March 2014 at four
public sector MDR-TB treatment sites in Namibia. Our
study included the four high burden sites that collect-
ively treated over 70 % of the MDR-TB cases in
Namibia, during the study period. These were the
Katutura, Oshakati, Rundu, and Walvis Bay MDR-TB
treatment facilities.
Study population and sample description
The study population comprised of patients receiving
treatment for MDR-TB at public sector facilities in
Namibia. Our study sample included all patients who
were clinically assessed and audiologically tested for
hearing function at baseline and at least once, after com-
mencing their MDR-TB treatment. Patients presenting
with symptoms of hearing loss prior to the start of
MDR-TB treatment were excluded from our cohort.
Upon suspicion or after being diagnosed with MDR-TB
infection, patients were initiated on six-to-eight months
of intensive phase treatment with a regimen that con-
tained either amikacin or kanamycin, until two sputum
smears and two successive cultures turned negative
for Mycobacterium tuberculosis. Thereafter, treatment
was changed to the continuous phase for 12–18
months that was administered on an outpatient basis.
The average daily patient dose of amikacin or kana-
mycin was 15 mg per kilogram body weight, although
dosing could be adjusted depending on the patient
age group, weight band and renal function [2]. Pa-
tients were tested for HIV infection and, if infected,
were enrolled on highly active antiretroviral treatment
according to the Namibian HIV treatment guidelines
that were current at that time [28].
Study outcome
The occurrence of hearing loss after initiation of MDR-
TB treatment was the main outcome of this study and
was determined by an audiologist using pure tone audi-
ometry as part of the usual care of patients treated for
MDR-TB infection at the sites. Audiometry was per-
formed at baseline, during the intensive phase of MDR-
TB treatment and also in the continuation phase. No
audiometry was done after completion of the MDR-TB
treatment for patients who did not develop hearing loss.
Hearing ability was tested by establishing the lowest in-
tensity of sound in decibels (dB) that the person could
hear at successive frequencies from 250 Hertz to 8,000
Hertz. Based on the audiogram chart provided by the
Namibian Ministry of Health and Social Services
(Additional file 1), the level of hearing was classified as
normal (0–20 dB), mild (21–40 dB), moderate (41–60 dB),
moderate-to-severe (61–80 dB), severe (81–100 dB), or
profound (101–120 dB). Although the thresholds are not
exactly the same, this classification of the severity of
hearing loss is similar to the one provided by the Ameri-
can Speech-Language-Hearing Association (ASHA) [29].
The potential confounders or effect modifiers of the
aminoglycoside exposure and hearing loss relationship
were patients’ baseline age and weight, sex, renal func-
tion, HIV status, year of treatment initiation and the
treatment site. Since capreomycin was reserved for use
in patients considered at risk of developing hearing loss
at the start, or at any time in the course of the intensive
phase of the MDR-TB treatment, its use was not in-
cluded in our study, to guard against confounding by in-
dication of this drug.
Data abstraction and processing
Data were abstracted from clinical records using a struc-
tured form, single-entered into Epi Info™ Version 7.1.4
software (July 2014; Centers for Disease Control and
Prevention, Atlanta, GA, USA) and the accuracy of entry
verified against the original paper forms. All patient
names and other identifiers were omitted from the final
dataset to protect their privacy and to ensure their confi-
dentiality. The anonymized and de-identified patient re-
cords were analyzed and reported in an aggregate
manner, except for one patient whose serial audiograms
have been anonymously published.
Data analysis
Data were summarized using descriptive statistics. We
compared continuous variables using the Student’s t-test
and categorical variables using the Chi-square test or
the Fisher exact test. We performed univariable un-
conditional logistic regression analysis to assess the
relationship between aminoglycoside use (amikacin or
kanamycin) and the occurrence of any hearing loss.
We repeated the same analysis for the less severe
forms of hearing loss (mild or moderate); and the
more severe forms of hearing loss (moderate-to-se-
vere, severe, or profound). We performed stratified
analyses to assess effect modification by patients’ age
group, sex, baseline body weight band and HIV status.
The Breslow-Day test of homogeneity was used to deter-
mine if the strata-specific odds ratios were similar. Multi-
variable logistic regression was conducted to adjust for
potential confounders for variables whose P-value for the
association with hearing loss was < 0.2. We used Epi Info™
Version 7.1.4 software (July 2014; Centers for Disease
Control and Prevention, Atlanta, GA, USA), for the
analysis.
Ethics statement
The study was approved by the institutional review board
(IRB) of the Utrecht University (Reference: UP1307) and
the research and ethics committee of the Namibian Minis-
try of Health and Social Services, (MoHSS), (Reference:
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17/3/3). A waiver of the requirement for informed consent
from the patients was requested from the IRB and the
MoHSS, because the study involved the review and
analysis of clinical data that are routinely collected as
part of the usual medical care of patients being
treated for MDR-TB in Namibia. All patient names
and other identifiers were omitted from the final
dataset to protect their privacy and to ensure their
confidentiality.
Results
There were 353 patients whose records were retrieved, all
of whom had documented normal hearing at the start of
their tuberculosis treatment. Fifty one (14 %) of the pa-
tients were treated with amikacin-based regimens and 302
(86 %) with kanamycin-based regimens. There were 164
patients (46 %) who were HIV co-infected, of whom 132
(80 %) were on highly active antiretroviral treatment.
These patient characteristics were comparable between
the amikacin and kanamycin-exposed groups (Table 1).
Subsequently, during the course of their MDR-TB
treatment, 206 of the patients (58 %) developed hearing
loss of any severity grading (Fig. 1 and Table 2). The
hearing loss was mild in 32 % of the patients, moderate
(23 %), moderate-severe (16 %), severe (10 %), or pro-
found (15 %) as shown in Table 2. Two-thirds (66 %) of
the patients with audiometrically confirmed hearing
damage needed to be fitted with an hearing aid or to
undergo speech rehabilitation.
The hearing loss was sensorineural and predominantly
bilateral (83 %), always beginning with high frequency
loss (4–8 kHz), and then progressing to involve the
lower frequencies (0.25–3 kHz) that are used for speech
and conversation as shown in one of the patient’s audio-
gram in Fig. 2. Patient X was a 36 years old male, weigh-
ing 53 kg at the start of MDR-TB treatment. His
treatment regimen for the intensive phase contained
amikacin, ethambutol, ethionamide and pyrazinamide.
The patient began experiencing loss of hearing after
about four months of treatment with this regimen. Ami-
kacin was stopped, but the patient continued experien-
cing the hearing loss after the cessation of amikacin. He
later developed profound hearing loss long after treat-
ment with amikacin was stopped.
The cumulative incidence of any hearing loss was
greater among patients treated with amikacin-based reg-
imens than in those treated with kanamycin-based regi-
mens (75 % versus 56 %, p = 0.01), (Table 3), and the
difference was largest for profound hearing (amikacin,
22 % versus kanamycin, 7 %, p = 0.01). Patients treated
with amikacin had more than twice the odds of kanamy-
cin of developing any hearing loss (crude odds ratio
(OR) = 2.3; 95 % CI 1.2–4.6), although the confidence
interval for the odds ratio for the association became
wider after adjusting for confounders (adjusted OR = 2.3;
95 % CI 1.0–5.4) as shown in Table 4. When the severity
of the hearing loss was taken into consideration, patients
treated with amikacin had a significantly greater risk of
Table 1 Baseline characteristics of the patients, by aminoglycoside exposure
All cases (N = 353)
Amikacin (n = 51) Kanamycin (n = 302) P- value
Age (years): mean ± SD 35.69 ± 9.56 36.47 ± 11.57 P = 0.85
Body weight (kgs): mean ± SD 49.58 ± 8.83 50.76 ± 12.0 P = 0.77
Sex:
Male, n (%) 32 (63 %) 166 (55 %) P = 0.47
Female, n (%) 19 (37 % 136 (45 %)
HIV co-infection: n (%) 25 (49 %) 139 (46 %) P = 0.53
DR-TB site:
Katutura 0 46 (15 %)
Oshakati 1 (2 %) 65 (22 %) P < 0.001
Rundu 0 67 (22 %)
Walvis Bay 50 (98 %) 124 (41 %)
Reporting period:
2004–2009, n (%) 45 (88 %) 48 (16 %) P < 0.001
2010–2011, n (%) 4 (8 %) 61 (20 %)
2012, n (%) 1 (2 %) 112 (37 %)
2013–2014, n (%) 0 80 (27 %)
Missing, n (%) 1 (2 %) 1 (0.3 %)
SD standard deviation, IQR interquartile range, HIV Human immunodeficiency virus
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experiencing the more severe forms of hearing loss
(adjusted OR = 4.0, 95 % CI: 1.5–10.8), than of devel-
oping the less severe forms (adjusted OR = 1.6, 95 %
CI: 0.6–4.5).
In stratified analyses by patients’ age group, baseline
body weight band and by HIV infection status respect-
ively, we noticed differences in the odds ratios of the
amikacin/kanamycin and hearing loss relationship in the
different strata of these variables. Although effect modi-
fication could not be statistically confirmed due to low
numbers, patients co-infected with HIV (crude OR = 3.4,
95 % CI: 1.1–10.6), males (crude OR = 4.5, 95 %1.5–13.4)
and those weighing 40–59 kg (crude OR = 2.8, 95 % CI:
1.1–6.8), appeared to be at higher risk of developing
hearing loss (Table 5).
Discussion
Adverse drug reactions are an important consideration
for patients treated for MDR-TB infection where the
prolonged treatment with amikacin or kanamycin is
likely to result in the development of permanent hearing
loss [16]. We report a high incidence of aminoglycoside-
induced hearing loss, which was more frequent in
patients treated with amikacin-based regimens than
in those containing kanamycin. The high cumulative
incidence of hearing loss (75 %) in the amikacin-
exposed group in our setting is similar to the 70 %
that was reported by Reza Javadi et. al. [30], while
the 56 % incidence for kanamycin is similar to the
58 % reported by Sataloff and colleagues [31]. This
provides compelling evidence that amikacin is more
ototoxic than kanamycin, in real-life clinical practice.
To the best of our knowledge, the current study is the
first one to quantify the comparative risk of hearing loss
of amikacin versus kanamycin in their real-life use for
MDR-TB treatment in a low-resource setting. It builds
on previous research from other settings, which sug-
gested that amikacin was associated with a greater risk
of hearing loss, but did not quantify the magnitude of
that risk [16]. Our finding is corroborated by the works
of Duggal and Sarkar as well as by Sturdy and colleagues
[16, 18] . In Duggal and Sarkar’s study, seven out of 34
patients (20.6 %) treated with amikacin for MDR-TB ex-
perienced sensorineural hearing loss involving the higher
frequencies while a lesser proportion of four out of 26
patients (15.4 %) treated with kanamycin experienced
the same type of hearing loss [18]. Similarly, Sturdy et.al.
monitored the occurrence of hearing loss in 50 MDR-TB
patients, 29 of whom were treated with amikacin, 11
with capreomycin and 10 with streptomycin, and found
Fig. 1 Study flow diagram depicting the presence or absence of hearing loss, by severity, in patients treated for MDR-TB
Table 2 The cumulative incidences of severity of hearing loss by type of aminoglycoside in the MDR-TB drug regimen












Mild 5 10 % 60 20 % 65 18 %
Moderate 7 14 % 41 14 % 48 14 %
Moderate-Severe 6 12 % 27 9 % 33 9 %
Severe 5 10 % 16 5 % 21 6 %
Profound 11 22 % 21 7 % 32 9 %
Missing severity grading 4 8 % 3 1 % 7 2 %
Total cases 38 75 % 168 56 % 206 58 %
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that the use of amikacin (P = 0.02) and decreased renal
function (P = 0.01) were significantly associated with the
development of hearing loss [16]. Although both studies
involved small numbers of patients, their findings have
been crucial in elucidating on the relative ototoxicity of
the aminoglycosides used in MDR-TB treatment. Con-
sidering our current findings and those of previous re-
search, we encourage clinicians and managers of the TB
control programs that are still using amikacin as the
preferred aminoglycoside for treating MDR-TB infec-
tion, to consider changing to kanamycin. Switching to
kanamycin and implementing other preventive measures,
will help to reduce the occurrence of aminoglycoside-
induced hearing loss among patients treated for MDR-TB.
The hearing loss seen in our study was sensorineural,
mostly bilateral and began by affecting higher frequen-
cies, then progressing to lower conversational-level fre-
quencies as the severity of deafness increased. This
finding is consistent with the pathophysiology of
aminoglycoside-induced hearing loss [4, 9]. After paren-
teral administration, aminoglycosides enter the inner ear
fluids of the organ of Corti and the sensory hair cells
where they are thought to react with heavy metal ions to
form highly reactive free radicals that damage the
Fig. 2 Serial audiograms for patient X, who developed profound hearing loss during MDR-TB treatment
Table 3 Amikacin versus kanamycin use in MDR-TB treatment
and the presence or absence of hearing loss
Aminoglycoside exposure Any hearing loss No hearing loss Total
Kanamycin 168 (56 %) 134 (44 %) 302
Amikacin 38 (75 %) 13 (25 %) 51
Total 206 147 353
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stereocilia of the sensory hair cells [32, 33]. There is
emerging evidence that the use of antioxidants like salic-
ylates, ion chelating agents or calcium-binding proteins
may prevent aminoglycoside-induced hearing loss [15,
34–37]. As illustrated in the case of patient X in this
paper, a patient’s hearing ability could continue deterior-
ating even after withdrawing the aminoglycoside due to
the long half-life or the sequestration of aminoglycosides
in the endolymph of the cochlea canals, which continues
to cause the loss of sensory hair cells long after stopping
the administration of the drug [7, 38].
We, therefore, advocate for MDR-TB treatment
programs to implement routine serial audiometry in pa-
tients treated with aminoglycosides even in resource
constrained settings, so that patients showing early signs
of hearing loss can be identified long before the damage
is too late to be reversed. When the drugs for preventing
aminoglycoside-induced hearing loss become licensed
for clinical use, they should be readily made available to
patients, as an additional means of protecting patients
from developing aminoglycoside-induced hearing loss.
The risk of aminoglycoside-induced hearing loss was
greatest in patients with lower baseline body weight
(40–59 kg). This could be due to a drug dosing problem
whereby clinicians may fail to titrate accurately the ami-
noglycoside doses according to individual patient body
weight. Alternatively, these could be patients who were
much sicker of tuberculosis disease than the heavier
weighing patients. Since we are unable to ascertain the
reason for this observation due to lack of data on serum
drug concentrations, we recommend further studies on
the long-term pharmacokinetics and pharmacodynamics
of aminoglycosides in the context of MDR-TB treatment,
taking into consideration patients’ renal function, an-
thropometric and genetic characteristics.
Patients co-infected with HIV were more at risk of
amikacin-induced hearing loss than the HIV uninfected
ones. There is emerging epidemiologic and clinical evi-
dence about the association between HIV infection and
hearing loss [27, 38, 39]. However, whether antiretroviral
medicines also induce hearing loss is a question that is
still unanswered because of the mixed findings of previ-
ous studies [25, 26, 40]. Besides, the current study
doesn’t shed light on this question because of a lack of
adequate data on the specific antiretroviral (ARV) drug
regimens used by the patients and insufficient patient
numbers, by ARV regimen. There is need for continued
research in this area to better understand the effect of
antiretroviral medicines on hearing ability.
Amikacin, kanamycin and other aminoglycosides are
practically not metabolized by the human body and are
excreted unchanged almost exclusively by glomerular fil-
tration, hence they require the careful monitoring of
their plasma levels during therapy [41, 42]. Unfortu-
nately, therapeutic drug monitoring (TDM) of the ami-
noglycoside plasma levels was not performed during the
Table 4 Relative risk of hearing loss of amikacin and kanamycin use in MDR-TB treatment
Any hearing loss Crude
OR (95 % CI)
Any hearing loss
aaOR (95 % CI)
Less severe hearing loss
aaOR (95 % CI)
More severe hearing loss
aaOR (95 % CI)
Kanamycin Reference Reference Reference Reference
Amikacin 2.3 (1.2–4.6) 2.3 (1.0–5.4) 1.6 (0.6–4.5) 4.0 (1.5–10.8)
Legend: aOR adjusted odds ratio, aadjusted for patient age, treatment site and year of treatment initiation; 95%CI =95 % confidence interval. Note that baseline
body weight band, sex, human immunodeficiency virus infection status were not adjusted for because they were potential effect-modifiers (see Table 5)
Table 5 Effect-modification of the amikacin or kanamycin exposure and the occurrence of hearing loss in MDR-TB treatment
Variable Strata Stratum-specific crude OR
(95 % Confidence Interval)
P-value (Breslow-Day test of
homogeneity across strata)
Age Age 0–24 years 2.0 (0.4–10.6)
Age 25–34 years 2.8 (0.8–9.2) 0.99
Age 35–44 years 2.6 (0.8–8.2)
Age 45+ years 3.0 (0.4–26.4)
Baseline body weight Weight 18–39 kgs NA
Weight 40–59 kgs 2.8 (1.1–6.8) 0.06
Weight 60+ kgs 1.1 (0.4–3.0)
Sex Female 1.1 (0.4–3.0) 0.06
Male 4.5 (1.5–13.4)
HIV status HIV negative 1.7 (0.7–4.1)
HIV positive 3.4 (1.1–10.6) 0.33
Legend: NA not possible to estimate due to some cells having zero values, kgs kilograms, HIV human immunodeficiency virus infection status
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treatment of patients for MDR-TB infection in Namibia.
This service was not available in the public sector health
system in Namibia and is not available in many develop-
ing countries [43], perhaps explaining the relatively high
incidence of ototoxicity reported among patients on
MDR-TB treatment in these countries. We recommend
that TB treatment programs in developing countries
should consider introducing routine therapeutic drug
monitoring for patients treated with aminoglycosides or
capreomycin, given the higher cost of correcting per-
manent hearing loss for the patient and the society. A
comparative cost-effectiveness analysis of conducting
TDM versus not doing TDM can further inform such a
strategy.
Renal clearance may strongly affect the toxicity of ami-
noglycosides [41, 42, 44]. The lack of data on renal clear-
ance for the patients included in our analysis is an
important limitation of the current study. Although we
retrieved the serum creatinine levels of 114 of the 353
patients from the laboratory database, the data was of no
benefit to this analysis because it represented creatinine
values that were measured at time points several months
after the initiation of the MDR-TB treatment and base-
line data were essentially missing. This, however, does
not mean that clinicians in Namibia do not assess pa-
tients on MDR-TB treatment for renal function. They do
so, but because of some practical challenges in the col-
lection of data for this study, we could not retrieve all
the data on serum creatinine levels for the patients in
our analysis. Nonetheless, we encourage clinicians in
our setting to systematically assess all patients on
MDR-TB treatment, or those at the greatest risk, for
renal function at baseline and over the course of the
treatment, as recommended by the Namibian TB
treatment guidelines [2].
Our study was an epidemiologic one, reflecting the
real-life usage of amikacin and kanamycin in routine clin-
ical practice. Using this study design, we identified patients
that were most-at-risk of developing aminoglycoside-
induced hearing loss. Importantly, hearing function was
assessed using audiograms, which were part of the routine
clinical follow-up of patients treated for MDR-TB.
However, the data on the time-to-onset of hearing
loss was unreliable because of the “batching” of pa-
tients for audiometry, due to the shortage of audiolo-
gists and audiology assistants.
Due to practical limitations about the documentation
of audiometry in patients treated for MDR-TB at the
sites prior to 2007, we could only retrieve information
on 51 patients that were treated with amikacin for the
period covered by this research. On the other hand, for
kanamycin, we retrieved 302 patients, causing an imbal-
ance in the numbers of patients exposed to amikacin
and kanamycin, respectively. To assess for possible bias,
the 51 patients on amikacin were checked for the risk of
hearing loss against 51 randomly selected patients on
kanamycin and the results were similar to those of the
353 patient sample.
There were several other limitations of this study. For
example, there were too few patients in some sub-groups
which limited the power of the study for multiple sub-
group analyses. Besides, we were unable to collect data on
other potential risk factors like the usage of antiretroviral
medicines in HIV infected patients, genetic markers of
ototoxicity and other unmeasured confounders including
the use of other medicines known to be ototoxic.
Conclusion
The long-term use of amikacin in MDR-TB treatment
led to a higher risk of the more severe forms of hearing
loss compared to the use of kanamycin for the same in-
dication. Males, patients with low baseline body weight
and those co-infected with HIV were most-at-risk. We
recommend that managers of MDR-TB treatment pro-
grammes should consider using kanamycin instead of
amikacin for the treatment of MDR-TB; and invest more
resources in building the capacity and skills of health
care personnel for routine renal, serum therapeutic drug
levels and audiometric monitoring of the most-at-risk
patients treated with aminoglycosides. More research
needs to be done to better understand the combined risk
of hearing loss in patients concomitantly treated for
MDR-TB and HIV infections. A better designed and
more powered study is needed to confirm the compara-
tive ototoxicity risk of amikacin and kanamycin; and as-
sociated risk factors.
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